Navigation Links
Imaging agents offer new view of inflammation, cancer
Date:10/7/2011

A series of novel imaging agents could make it possible to "see" tumors in their earliest stages, before they turn deadly.

The compounds, derived from inhibitors of the enzyme cyclooxygenase-2 (COX-2) and detectable by positron emission tomography (PET) imaging, may have broad applications for cancer detection, diagnosis and treatment.

Vanderbilt University investigators describe the new imaging agents in a paper featured on the cover of the October issue of Cancer Prevention Research.

"This is the first COX-2-targeted PET imaging agent validated for use in animal models of inflammation and cancer," said Lawrence Marnett, Ph.D., director of the Vanderbilt Institute of Chemical Biology and leader of the team that developed the compounds.

COX-2 is an attractive target for molecular imaging. It's not found in most normal tissues, and then it is "turned on" in inflammatory lesions and tumors, Marnett explained.

"As a tumor grows and becomes increasingly malignant, COX-2 levels go up," Marnett said.

To develop compounds that target COX-2 and can be detected by PET imaging, Jashim Uddin, Ph.D., research assistant professor of Biochemistry, started with the "core" chemical structures of the anti-inflammatory medicines indomethacin and celecoxib and modified them to add the element fluorine in various chemical configurations.

After demonstrating that the fluorinated compounds were selective inhibitors of COX-2, the investigators incorporated radioactive fluorine (18-F) into the most promising compound. Intravenous injection of this 18-F compound into animal models provided sufficient signal for PET imaging.

The researchers demonstrated the potential of this 18-F compound for in vivo PET imaging in two animal models: irritant-induced inflammation in the rat footpad and human tumors grafted into mice.

They showed that the 18-F compound accumulated in the inflamed foot, but not the non-inflamed foot, and that pre-treatment of the animals with celecoxib blocked the signal. In mice bearing both COX-2-positive and COX-2-negative human tumors, the 18-F compound accumulated only in the COX-2-positive tumor.

The studies support further development of these agents as probes for early detection of cancer and for evaluation of the COX-2 status of pre-malignant and malignant tumors.

"Because COX-2 levels increase during cancer progression in virtually all solid tumors, we think these imaging tools will have many, many different applications," Marnett said.


'/>"/>

Contact: Leigh MacMillan
leigh.macmillan@vanderbilt.edu
615-322-4747
Vanderbilt University Medical Center
Source:Eurekalert

Related medicine news :

1. New research shows PET imaging effective in predicting lung cancer outcomes
2. Researchers transform iPhone into high-quality medical imaging device
3. Consider the breast and lungs when determining thoracic imaging protocols
4. Stanford brain imaging study shows physiological basis of dyslexia
5. New diagnostic imaging for lung cancer could prevent unnecessary surgery
6. Error rate higher in breast imaging reports generated by automatic speech recognition
7. Experts offer solutions at ACR Imaging Informatics Summit & Radiation Dose Monitoring Forum
8. New imaging technique visualizes cancer during surgery
9. Researchers utilize neuroimaging to show how brain uses objects to recognize scenes
10. New hybrid imaging device shows promise in spotting hard-to-detect ovarian cancer
11. New imaging test gives physicians better tool to diagnose Parkinsons disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are ... with endometriosis. These women need a treatment plan to not only alleviate symptoms ... can help for preservation of fertility and ultimately achieving a pregnancy. The specialists ...
(Date:6/25/2016)... ... 2016 , ... Austin residents seeking Mohs surgery services, can now turn to ... Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to ... fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users ... - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 ... Pro X . Simply select a ProHand generator and drag it above media or ...
(Date:6/25/2016)... Beach, CA (PRWEB) , ... June 25, 2016 , ... ... UCLA with Magna Cum Laude and his M.D from the David Geffen School of ... Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at the ...
(Date:6/25/2016)... , ... June 25, 2016 , ... On Friday, June ... a Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments ... of the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... CHAPEL HILL, N.C. , June 24, 2016 ... in healthcare decisions and regulators/payers have placed more ... this new environment, patient support programs in the ... support for patients, medications. Consequently, pharmaceutical companies are ... to ensure they are providing products and services ...
(Date:6/24/2016)... FRANCISCO, Calif. , June 24, 2016 /PRNewswire/ ... ), a biopharmaceutical company developing novel therapeutics for ... unmet needs, today announced the closing of its ... of common stock, at the public offering price ... in the offering were offered by GBT. GBT ...
(Date:6/24/2016)... 2016 Dublin ... addition of the " Global Markets for Spectroscopy ... This report focuses on the ... review, including its applications in various applications. The report ... includes three main industries: pharmaceutical and biotechnology, food and ...
Breaking Medicine Technology: